Avodart May Reduce the Risk of Developing Prostate Cancer

While many hair loss sufferers are awaiting GlaxoSmithKline’s release of its clinical study results on the use of Avodart (dutasteride) for treating male pattern baldness, a different study by the GlaxoSmithKline Group has been released recently. It shows that Avodart, which is already used to shrink enlarged prostates could also help reduce the risk of developing prostate cancer. This is practically in line with what we already know about a similar drug used for the treatment of benign prostatic hyperplasia and baldness in men – finasteride (Proscar/Propecia). Because it is too early to say whether finasteride or dutasteride are able to significantly reduce the risk of developing prostate cancer, there is no consensus at the moment amongst the experts regarding the use of these hormone-blocking drugs as prostate cancer prevention agents. However, as some doctors suggest for men with significant prostate cancer risk factors, it may be prudent to consider the use of either Proscar or Avodart at low doses for prevention of prostate cancer.